-
1 week ago | 
nutraceuticalbusinessreview.com | Kevin Robinson
The global prebiotic-fibre segment is surging as consumers look beyond basic gut health toward holistic benefits spanning metabolic, cardiovascular and even cognitive wellness.
In Europe alone, the prebiotic market was valued at $3.71 billion in 2024, is projected to reach $4.18 billion in 2025 and could climb to $10.77 billion by 2033 (at CAGR of approximately 12.6%).
-
2 weeks ago | 
manufacturingchemist.com | Kevin Robinson
By Kevin Robinson | Published: 10-Jun-2025 Spatial biology is the study of biomolecules and cells within their native tissue microenvironment. This approach has enabled scientists to develop a better understanding of cell interactions in their natural locations You need to be a subscriber to read this article. Click here to find out more.
-
1 month ago | 
nutraceuticalbusinessreview.com | Kevin Robinson
By Kevin Robinson | Published: 6-May-2025 Consumers are increasingly prioritising health, value and taste in their food choices, which is driving demand for functional and healthier products without compromising flavour. Dr Kevin Robinson (KSR) talked to Lin Peterse, Category Development Manager at Tate & Lyle, to find out more You need to be a subscriber to read this article. Click here to find out more.
-
2 months ago | 
nutraceuticalbusinessreview.com | Kevin Robinson
Dr Kevin Robinson spoke to Diana Roldan, Nektium’s Scientific Product and Communication Manager, to find out more.
In an ever busier and more unsettled world, managing stress has become a key priority for consumers globally.
-
2 months ago | 
manufacturingchemist.com | Kevin Robinson
By Kevin Robinson | Published: 4-Apr-2025 As the CEO of Symbiosis, a contract manufacturing organisation (CMO) licenced to manufacture sterile medicinal products, Colin MacKay understands the profound responsibility involved in ensuring that the products they manufacture meet the highest quality standards and adhere to all relevant regulatory requirements You need to be a subscriber to read this article. Click here to find out more.
-
Mar 10, 2025 | 
manufacturingchemist.com | Kevin Robinson
Thierry Van Nieuwenhove, CEO of Quotient Sciences recognises that sustainability and resilience are critical to the future of pharmaceutical development supply chains.
As an industry, we must balance the need for innovation and speed with responsible environmental stewardship.
Our ESG commitments at Quotient are deeply embedded in our mission to accelerate the development of new medicines while minimising our environmental impact.
-
Feb 11, 2025 | 
manufacturingchemist.com | Kevin Robinson
By Kevin Robinson | Published: 10-Feb-2025 Dr Kevin Robinson recently caught up with pharmaceutical industry experts to review what they considered to be the sector’s key challenges and achievements in 2024 and what trends, technologies or regulatory shifts they anticipate will shape the industry in 2025 You need to be a subscriber to read this article. Click here to find out more.
-
Jan 12, 2025 | 
manufacturingchemist.com | Kevin Robinson
By Kevin Robinson | Published: 13-Jan-2025 Ahead of Pharmapack Europe 2025 (22–23January, Paris, France), Dr Kevin Robinson (KSR) spoke with three pharma leaders about the big trends that will drive and influence the pharmaceutical sector in 2025 You need to be a subscriber to read this article. Click here to find out more.
-
Dec 9, 2024 | 
nutraceuticalbusinessreview.com | Kevin Robinson
As Clasado marks its 20th anniversary, it provides an opportunity to reflect not just on our own journey but on the remarkable evolution of the wider prebiotics category.
What began as a niche ingredient segment has transformed into one of the fastest-growing areas in health and nutrition that’s projected to see a robust compound annual growth rate of nearly 15% to 2030.
-
Nov 27, 2024 | 
manufacturingchemist.com | Kevin Robinson
At ILC Therapeutics (ILCT), we are pioneering a novel drug class called hybrid interferons, Dawn Firmin, Chief Operating Officer, tells Dr Kevin Robinson.
This is being driven by our platform technology, which has so far delivered two engineered cytokine candidates that are progressing towards the clinic. This article explores the journey so far, some of the specific challenges that have arisen and how we have faced them.
